| 133.13 -5.84 (-4.2%) | 01-30 15:47 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 163.22 |
1-year : | 177.36 |
| Resists | First : | 139.74 |
Second : | 151.85 |
| Pivot price | 138.85 |
|||
| Supports | First : | 120.17 |
Second : | 99.98 |
| MAs | MA(5) : | 138.08 |
MA(20) : | 136.96  |
| MA(100) : | 126.3 |
MA(250) : | 111.57 |
|
| MACD | MACD : | 1.8 |
Signal : | 2.4 |
| %K %D | K(14,3) : | 28.6 |
D(3) : | 41.7 |
| RSI | RSI(14): 46.5 |
|||
| 52-week | High : | 156 | Low : | 62.07 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ TMDX ] has closed above bottom band by 5.1%. Bollinger Bands are 43.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 145.14 - 145.85 | 145.85 - 146.43 |
| Low: | 133.5 - 134.44 | 134.44 - 135.19 |
| Close: | 137.65 - 139.08 | 139.08 - 140.24 |
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 34 (M) |
| Shares Float | 33 (M) |
| Held by Insiders | 2.9 (%) |
| Held by Institutions | 111.3 (%) |
| Shares Short | 7,200 (K) |
| Shares Short P.Month | 7,720 (K) |
| EPS | 2.53 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 10.39 |
| Profit Margin | 16.2 % |
| Operating Margin | 16.2 % |
| Return on Assets (ttm) | 6.9 % |
| Return on Equity (ttm) | 32.4 % |
| Qtrly Rev. Growth | 32.2 % |
| Gross Profit (p.s.) | 9.99 |
| Sales Per Share | 16.57 |
| EBITDA (p.s.) | 3.52 |
| Qtrly Earnings Growth | 450.1 % |
| Operating Cash Flow | 178 (M) |
| Levered Free Cash Flow | 87 (M) |
| PE Ratio | 52.21 |
| PEG Ratio | 0 |
| Price to Book value | 12.75 |
| Price to Sales | 8 |
| Price to Cash Flow | 25.46 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |